Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

Core Points - Microbot Medical Inc. announced the third and final closing of its preferred investment options, resulting in the issuance of 13,989,115 shares of common stock [1][4] - The total gross proceeds from the three closings amounted to approximately $29.2 million, with potential additional proceeds of about $63 million from the exercise of short-term preferred investment options [4] Group 1: Investment Details - The first closing generated approximately $25.2 million from the exercise of options for 12,064,627 shares at prices ranging from $1.50 to $2.13 per share [2][4] - The second closing brought in approximately $1.2 million for 600,000 shares at an exercise price of $2.10 per share [2][4] - The third closing resulted in approximately $2.8 million for 1,324,488 shares at an exercise price of $2.10 per share [2][4] Group 2: Future Plans and Use of Proceeds - The company plans to utilize the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4] - The new short-term series J preferred investment options will have an exercise price of $4.50 per share and will be exercisable six months after issuance [2][4] Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being a key product [7][8] - The company is backed by a strong intellectual property portfolio and is committed to innovation in endovascular care [8]